Brent Saunders, Allergan president & CEO, discusses the strategy behind selling its generic unit to Teva Pharmaceuticals.
Brent Saunders, Allergan president & CEO, discusses selling Allergan's generic unit to Teva Pharmaceutical for $40.5 billion.
Teva Pharmaceutical Industries will buy the generic drug division of Allergan Plc, reports the "Squawk Box" crew.
Botox-maker Allergan is buying Kythera Biopharmaceuticals in a $2.1 billion deal.
Allergan President and CEO Brent Saunders, discusses the name change from Actavis, and the outlook for botox.
The all-cash deal could be announced as soon as Sunday, according to these sources who requested not to be identified.